Geron | GERN

Stock Price
3.69
Daily Change
3.65%
Yearly
161.70%
Q2 Forecast
3.50
Rating
Sell

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Amgen 220.76 -0.49 -0.22% -8.68%
CTI Biopharma 9.05 0.01 0.11% 48.85%
Cytokinetics 38.06 -0.67 -1.73% -2.01%
Esperion Therapeutics 1.35 -0.01 -0.74% -76.44%
Exelixis 19.35 0.08 0.42% 2.49%
Genmab 2,688.00 -2.00 -0.07% 27.82%
Geron 3.69 0.13 3.65% 161.70%
Gilead Sciences 78.40 2.32 3.05% 28.15%
Incyte Corp 61.51 0.12 0.20% -15.49%
MacroGenics 5.20 -0.05 -0.95% 69.38%
Novartis 90.37 0.87 0.97% 5.91%
Novavax 7.69 0.02 0.26% -81.46%
Cassava Sciences Inc. 24.48 0.47 1.96% -5.37%
Seattle Genetics 194.72 -0.03 -0.02% 37.37%
Bio Techne 79.29 -2.96 -3.60% -10.77%

Indexes Price Day Year
USND 13239 133.63 1.02% 12.63%
US2000 1881 -7.67 -0.41% 1.62%

Geron

Geron traded at $3.69 this Thursday June 8th, increasing $0.13 or 3.65 percent since the previous trading session. Looking back, over the last four weeks, Geron gained 31.32 percent. Over the last 12 months, its price rose by 161.70 percent. Looking ahead, we forecast Geron to be priced at 3.50 by the end of this quarter and at 3.20 in one year, according to Trading Economics global macro models projections and analysts expectations.

Geron Corporation is a late-stage clinical biopharmaceutical company, which is focused on the development and commercialization of imetelstat, a therapeutic for hematologic myeloid malignancies. The Company operates through a single segment, which is engaged in the development of therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. The clinical studies of imetelstat include IMerge, a Phase III trial in lower risk myelodysplastic syndromes (MDS) and IMbark, a Phase II trial in Intermediate- II or High-risk myelofibrosis. Its IMpactMF is an ongoing Phase III clinical trial in refractory myelofibrosis (MF).